Protox Therapeutics to present TRIUMPH clinical study update

NewsGuard 100/100 Score
Sep 9 2009

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that Dr. Fahar Merchant, President & CEO of Protox Therapeutics, will present at the 11th Annual Rodman & Renshaw Healthcare Conference. The conference runs from Wednesday, September 9 through Friday, September 11 at the Palace Hotel in New York City. Dr. Merchant's presentation is at 9:10 a.m. ET on Friday, September 11 in the Garrison Salon on the 5th floor of the hotel and will be webcast live from Protox's website.

Dr. Merchant will present the corporate story and upcoming milestone highlights, including an update on TRIUMPH, a double-blinded placebo controlled Phase 2b study of PRX302 in patients with benign prostatic hyperplasia (BPH). Dr. Merchant will also be presenting 12-month data from the Phase 2a open-label BPH study.

Source: PROTOX THERAPEUTICS INC.

Posted in: Drug Trial News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Vaccines targeting chronic diseases show promise in combatting age-related conditions
Promising candidate medication for preventing and reversing fentanyl-induced overdose
AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial
Revvity Signals Software unveils Signals Clinical solution to accelerate critical clinical trial insights and data-driven decisions
Natural compounds show promise in modulating heme breakdown, offering new therapeutic avenues
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke
Natural killer cells lead the charge in cancer treatment innovation
Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New peptide library paves the way for targeting elusive cancer factor MYC